Literature DB >> 15149583

Treatment of Hereditary Colorectal Cancer Syndromes.

Elizabeth E. Half1, Robert S. Bresalier.   

Abstract

Colorectal cancer is the second leading cause of cancer-related death in the United States. Although most colorectal cancers are sporadic, about 25% have a familial predisposition and 5% to 7% are hereditary and occur in genetically distinct high-risk families. Advances in treatment options and management of hereditary colorectal cancer syndromes that have occurred over the past years have been principally due to advances in the understanding of the genetics of these syndromes and in additional options for testing. This has led to the possibility of preclinical diagnosis and early surveillance and treatment. In addition, improvements in medical and surgical management have also occurred. This article focuses on four hereditary colon cancer syndromes: familial adenomatous polyposis, hereditary non-polyposis colorectal cancer, juvenile polyposis syndrome, and Peutz-Jeghers syndrome.

Entities:  

Year:  2004        PMID: 15149583     DOI: 10.1007/s11938-004-0042-0

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  37 in total

1.  American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing.

Authors: 
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

Review 2.  The risk of gastrointestinal carcinoma in familial juvenile polyposis.

Authors:  J R Howe; F A Mitros; R W Summers
Journal:  Ann Surg Oncol       Date:  1998-12       Impact factor: 5.344

Review 3.  Prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer.

Authors:  J M Church
Journal:  Ann Med       Date:  1996-12       Impact factor: 4.709

4.  Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis.

Authors:  M G Sayed; A F Ahmed; J R Ringold; M E Anderson; J L Bair; F A Mitros; H T Lynch; S T Tinley; G M Petersen; F M Giardiello; B Vogelstein; J R Howe
Journal:  Ann Surg Oncol       Date:  2002-11       Impact factor: 5.344

5.  Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families.

Authors:  Wouter H de Vos tot Nederveen Cappel; Fokko M Nagengast; Gerrit Griffioen; Fred H Menko; Babs G Taal; Jan H Kleibeuker; Hans F Vasen
Journal:  Dis Colon Rectum       Date:  2002-12       Impact factor: 4.585

6.  Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage.

Authors:  G M Petersen; J Slack; Y Nakamura
Journal:  Gastroenterology       Date:  1991-06       Impact factor: 22.682

7.  Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair.

Authors:  M Strand; T A Prolla; R M Liskay; T D Petes
Journal:  Nature       Date:  1993-09-16       Impact factor: 49.962

8.  Pancreas-preserving duodenectomy in the management of duodenal familial adenomatous polyposis.

Authors:  Matthew F Kalady; Bryan M Clary; Douglas S Tyler; Theodore N Pappas
Journal:  J Gastrointest Surg       Date:  2002 Jan-Feb       Impact factor: 3.452

9.  A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.

Authors:  R K S Phillips; M H Wallace; P M Lynch; E Hawk; G B Gordon; B P Saunders; N Wakabayashi; Y Shen; S Zimmerman; L Godio; M Rodrigues-Bigas; L-K Su; J Sherman; G Kelloff; B Levin; G Steinbach
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

10.  Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome.

Authors:  M G Dunlop
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

View more
  1 in total

1.  In the beginning there was colectomy: current surgical options in familial adenomatous polyposis.

Authors:  Daniel R McGrath; Allan D Spigelman
Journal:  Hered Cancer Clin Pract       Date:  2004-11-15       Impact factor: 2.857

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.